Showing results (291-300 of 342) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2025
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 TrialMohamad Mohty, Gerard Socié, Jeff Szer, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|July 1, 2022
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trialAbby Douglas, Karin Thursky, Timothy Spelman, et al.
Haematologica|February 15, 2020
Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromesPiers Blombery, Lucy Fox, Georgina L Ryland, et al.
Haematologica|January 18, 2020
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky, Régis Peffault de Latour, Scott T Rottinghaus, et al.
Blood|April 21, 2010
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remissionDavid I Marks, Tao Wang, Waleska S Pérez, et al.
Internal Medicine Journal|June 20, 2017
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapseAndrew B M Lim, Cameron Curley, Chun Y Fong, et al.
Blood|December 5, 2018
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 studyAustin G Kulasekararaj, Anita Hill, Scott T Rottinghaus, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
Pageof 35